Project Grant R01DK144772
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $742,478 on July 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to elucidate how RNA-lipid nanoparticle transfection and expression in professional antigen-presenting cells and non-professional antigen-presenting cells—specifically hepatocytes and skeletal myocytes—modulate T cell responses to RNA-encoded protein. The...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $889,856 on August 17, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate mechanisms by which metabolic-associated fatty liver disease (MASH) drives chronic kidney disease pathogenesis. The recipient will conduct three specific research aims over the performance period through April 30, 2031. Aim 1 confirms the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $816,825 on April 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate how injured podocytes communicate with parietal epithelial cells to drive proliferative glomerulopathy, specifically whether podocyte-derived exosomes mediate this cell-to-cell signaling in rapidly progressive glomerulonephritis. The research uses...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $910,670 to Icahn School of Medicine at Mount Sinai on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to characterize a cluster of single-nucleotide polymorphisms (SNPs) in the LILRB3 gene associated with post-transplant renal failure in kidney transplant recipients. The research characterizes four consecutive SNPs in LILRB3 that encode missense mutations...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $571,200 on August 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct basic research on mechanisms protecting pancreatic beta cells from dysfunction and death in diabetes. The award funds research into a novel small molecule compound (Compound 43) that acts as a molecular glue to stabilize the interaction between the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $100,228 on February 13, 2027, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research on PINK1 regulation of terminal erythroid maturation and red blood cell enucleation. The research tests the physiological role of PINK1 (PTEN-induced kinase 1) in terminal erythroid maturation and enucleation—the process by which...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $672,000 on August 14, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a randomized feasibility trial testing isocaloric navy bean substitution as a dietary intervention in adults with metabolic dysfunction-associated steatotic liver disease and advanced fibrosis. The recipient will conduct a single-site, 24-week,...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $726,142 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of microbiota-specific T cells in inflammatory bowel disease. The research uses deep single-cell RNA and T cell receptor sequencing technologies to longitudinally profile T cell repertoire and phenotype in two parallel studies: human...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $871,028 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate iron trafficking mechanisms in myelodysplastic syndrome erythropoiesis. The recipient will conduct research examining how excess iron impairs red blood cell production in MDS patients and whether modulating iron trafficking can restore effective...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $155,832 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate matrix metalloproteinase-7 (MMP7)–expressing hepatic stellate cells as drivers of fibrosis progression in biliary atresia. The funded project will define the transcriptomic and spatial identity of MMP7+ hepatic stellate cells in biliary atresia...
The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $874,673 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate how suppression of 5-aminolevulinic acid synthase 1 (ALAS1) enhances therapeutic RNA interference activity. The project tests a novel genetic strategy to improve the efficacy of small interfering RNAs (siRNAs) in extrahepatic tissues where siRNA delivery remains challenging. Research will proceed through three aims: delineating the molecular mechanism by which ALAS1 inhibits microRNA accumulation; testing whether ALAS1 suppression enhances siRNA-mediated gene silencing in liver hepatocytes and in three difficult-to-transfect cell types (brain neurons, lung alveolar cells, and renal tubule cells) using both in vitro and in vivo models; and determining the safety profile of ALAS1 ablation in these cell types through generation of inducible, conditional knockout mice. The project leverages the fact that ALAS1 is already the target of Givosiran, an FDA-approved siRNA therapeutic, providing clinical precedent for the safety of ALAS1 suppression. Work is performed in New York, NY (10029) with a period of performance from August 15, 2026 through May 31, 2031. The assistance type is Project Grant.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $874.7k | 8/5/26 |